Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
https://doi.org/10.17650/1818-8346-2008-0-3-52-62
Abstract
The characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are presented. A hundred and twenty-four patients with recurrent/refractory MM and 14 primary patients were followed up. PN more commonly occurred after 3—5 cycles of bortezomib therapy. Grade > 2 PN was observed in 29% of the patients. The cumulative dose of bortezomib was 15.6 to 26 mg/m2. After 6—8 cycles the incidence of PN was also high. There was a correlation between the cumulative dose of bortezomib and the incidence of PN (R = 0.927; p < 0.0009). A correlation was also found between the incidence of PN and prior vincristine-containing treatment regimens (VAD scheme). Overall, PN was identified in 54% of the patients. Treatment of PN with gabapentin, pregabalin, vitamins B, and α-lipoic acid was effective. PN resolved to the baseline levels or the patients’ condition improved in 72% of the patients, the median time taken for resolution or improvement being 114 days. It is necessary to reduce the dose of bortezomib or to discontinue the drug temporarily in order to relieve the symptoms of neuropathy.
About the Authors
S. S. Bessmeltsev
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
E. V. Karyagina
City Hospital Fifteen
Russian Federation
Russian Federation
Saint Petersburg
L. V Stelmashenko
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
N. V. Stepanova
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
E. R. Machulaiten
I.P. Pavlov Saint Petersburg State Medical University
Russian Federation
Russian Federation
G. N. Salogub
I.P. Pavlov Saint Petersburg State Medical University
Russian Federation
Russian Federation
I. A. Skorokhod
City Hospital Thirty One
Russian Federation
Russian Federation
N. V. Medvedeva
City Hospital Thirty One
Russian Federation
Russian Federation
E. I. Podoltseva
City Hospital Thirty One
Russian Federation
Russian Federation
L. M. Matyukhina
Road Hospital, AOA “RZhD”
Russian Federation
Russian Federation
A. S. Nizamutdinova
Alexandrov Hospital
Russian Federation
Russian Federation
Saint Petersburg
K. M. Abdulkadyrov
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
References
1. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему. Алматы, 2007.
2. Mileshkin L., Antil Y., Rischin D. Management of complications of chemotherapy. In: Gynaecologic Cancer: Controversies in Management. D.M. Gershenson, M.P. McGuire, M. Gore et al (eds). Philadelphia, PA, Elsevier Science, 2002.
3. Barohn R. Approach to peripheral neuropathy and neuronopathy. Semin Neurol 1998;18:7—18.
4. Lopate G., Parks B., Goldstein J. et al. Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins. J Neurol Neurosurg Psychiatry 1997;62:581—5.
5. Шакирова И.Н. Нейротоксичность современных цитостатиков. VI Российская онкологическая конференция (26—28 ноября 2002 г.). www.rosoncoweb.ru/library/6th_conf/18.html
6. Bromberg M.B. An approach to the evaluation of peripheral neuropathies. Semin Neurol 2005;25:153—9.
7. Smith A., Bromberg M. A rational diagnostic approach to peripheral neuropathy. J Clin Neuromusc Dis 2003;4:190—8.
8. Kelly J.J., Kyle R.A., O'Brien P.C., Dyck P.J. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31:1480—3.
9. Cook L., Macdonald D.H.C. Management of paraproteinaemia. Postgrad Med J 2007;83:217—23.
10. Dispenzieri A., Kyle R.A. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 2005;8:673—88.
11. Ropper A.H., Gorson K.C. Neuropathies associated with paraproteinemia. N Engl J Med 1998;338: 1601—7.
12. Bataille R., Harousseau J.-L. Multiple myeloma. N Engl J Med 1997;336:1657—64.
13. Rajkumar S.V. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology (The American Society of Hematology) 2005;1:340.
14. Brenner B., Carter E., Tatarsky I. et al. Incidence, prognostic significance and therapeutic modalities of antral nervous system involvement in multiple myeloma. Acta Haematol 1982;68:77—83.
15. Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609—17.
16. Singhal S., Mehta J., Desikan R. et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565—71.
17. Pal P.K. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 1999;39:323—30.
18. Singhal S., Mehta J. Thalidomide in cancer: Potential uses and limitations. BioDrugs 2001;15:163—72.
19. Mileshkin L., Stark R., Day B. et al. Development of neuropathy in patients with myeloma treated with thalidomide. Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24(27):4507—14.
20. Offidani M., Corvatta L., Marconi M. et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma. Focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004;72:403—9.
21. Briani C., Zara G., Rondinone R. et al. Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus. Neurology 2004;62: 2288—90.
22. Richardson P.G., Briemberg H., Jagannath S. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113—20.
23. Bang S.M., Lee J.H., Yoon S.S. et al. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol 2006;83:309—13.
24. Бессмельцев С.С., Стельмашенко Л.В., Подольцева Э.И. и др. Первый отечественный опыт применения бортезомиба (велкейда) в лечении рефрактерных и рецидивирующих форм множественной миеломы. Вестн гематол 2007;(1):16—23.
25. Бессмельцев С.С., Стельмашенко Л.В., Подольцева Э.И. и др. Бортезомиб (велкейд) в комбинации с дексаметазоном при рецидиве и рефрактерных формах множественной миеломы. Онкогематология 2007;(4):61—6.
26. Colson K., Doss D.S., Swift R. et al. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs 2004;8:473—80.
27. Чернышева Т. Е. Витамины группы В в комплексной терапии диабетической нейропатии. Рос мед вести 2001;(4):48—51.
28. Loew D. Pharmacokinetics of thiamine derivatives especially of benfothiamine. Int J Clin Pharmacol Therap 1996;34:47—50.
29. Jermendy G. The effectiveness of Milgamma in treatment of diabetic polyneuropathy. Medicuc Universalis 1995;5:217—20.
30. Low P.A., Nickander K.K. et al. The role oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997;46(Suppl 2): 38—42.
31. Ziegler D., Hanefeld M., Ruhnau K.J., Gries F.A. The ALADIN Srudy Group. Treatment of symptomatic peripheral neuropathy with the antioxidant (lipoic acid). Diabetoloogia 1995;38:1425—33.
32. Ziegler D., Schatz H., Conrad F. et al. Effects of treatment with antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. Diabetes Care 1997;20:369—73.
33. Данилов А.Б. Нейропатическая боль. М.: Нейромедиа, 2004.
34. Gorson K.C., Schott C., Rand W.M. et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebocontrolled, double-blind, crossover trial. Neurology 1998;50(Suppl 4):A103.
35. Freynhagen R., Strojek K., Griesing T. et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254—63.
36. Fehrenbacher J.C., Taylor C.P., Vasko M.R. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133—41.
37. Levien T.L. Summary of new drug applications and biologic license applications submitted to the Food and Drug Administration: Pregabalin-Pfizer. Advances in Pharmacy 2004;2:185—6.
38. Curran M.P., Wagstaff A.J. Gabapentin in postgerpetic neuralgia. CNS Drugs 2003;17:975—82.
39. Backonja M., Beydoun A., Edwards K.R. et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831—6.
40. Morello C.M., Leckband S.G., Stoner C.P. et al. Randomized doubleblind study comparing the efficacy of gabapentin with amitriptyline on diabetic neuropathy pain. Arch Intern Med 1999;159:1931—7.
41. Rosenstock J., Tuchman M., LaMoreaux L., Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebocontrolled trial. Pain 2004;110:628—38.
42. Lesser H., Sharma U., LaMoreaux L., Poole R.M. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104—10.
43. Richter R.W., Portenoy R., Sharma U. et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253—60.
44. Jarvis B., Coukell A.J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998;56:691—707.
45. Rowbotham M., Harden N., Stacey B. et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837—42.
46. Shneker B.F., McAuley J.W. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029—37.
47. Boulton A.J.M., Scarpello J.H.B., Armsrtong W.D., Ward J.D. The natural history of painful diabetic neuropathy a 4-year study. Postgrad Med J 1996;59: 556—9.
48. Horrobin D.F. Essential Fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997;46 (Suppl 2):90—3.
49. Alpha-Linolenic acid may lower risk of diabetic peripheral neuropathy. Diabetes Care 2008;31:93—5.
50. Malik R.A., Williamson S., Carrington A.L., Boulton A.J.M. Effect of angiotensinconvertingenzume (ACE) inhibitor trandolapril on human diabetic neuropathy: randomized doubleblind controlled trial. Lancet 1998;352:1978—81.
51. Apfel S.C., Kessler J.A., Adornato B.T. et al. The NGF study Group. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695—702.
52. Cameron N.E., Cotter M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46(Suppl 2):S31—S37.
53. Hildegarde J.B. Neuropathic Pain: diagnosis, treatment, and the pharmacist's role in patient care. Pharm Times 2005;97—108.
54. Richardson P.G., Sonneveld P., Schuster M.W. et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352: 2487—98.
55. Oakervee H.E., Popat R., Curry N. et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755—62.
Review
For citations:
Bessmeltsev S.S., Karyagina E.V., Stelmashenko L.V., Stepanova N.V., Machulaiten E.R., Salogub G.N., Skorokhod I.A., Medvedeva N.V., Podoltseva E.I., Matyukhina L.M., Nizamutdinova A.S., Abdulkadyrov K.M. Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade). Oncohematology. 2008;(3):52-62. (In Russ.) https://doi.org/10.17650/1818-8346-2008-0-3-52-62
Views:
265
Email this article 